Evaluation of evening versus morning levothyroxine intake in elderly (MONIALE)

Karina Giassi, Vanessa Piccoli, Ticiana da Costa Rodrigues, Renato Gorga Bandeira de Mello, Karina Giassi, Vanessa Piccoli, Ticiana da Costa Rodrigues, Renato Gorga Bandeira de Mello

Abstract

Background: The aging population is associated with increased multimorbidity and polypharmacy. Older adults are at a higher risk of adverse events and reduced therapeutic response. This phenomenon is partially explained by drug interactions and treatment adherence. Most randomized clinical trials have found no significant differences between morning and evening levothyroxine (LT4) administration in young adults, but there is little evidence regarding alternative LT4 regimens in older populations. Thus, the MONIALE trial aims to test an alternative schedule for LT4 administration in older adults.

Methods/design: This randomized crossover clinical trial will include participants aged 60 years or older with primary hypothyroidism. The trial groups will consist of morning LT4 intake (60 min before breakfast) or evening LT4 intake (60 min after supper). The primary outcome will be variation in serum thyrotropin (TSH) levels after 24 weeks of the LT4 protocol. The secondary outcomes will be the prevalence of drugs that potentially interact with LT4 and hypothyroidism control according to interaction status. The sample size was calculated to detect a minimum mean difference of 1 mUI/L in serum TSH level between the groups with 80% power and a 5% probability of type I error, resulting in 91 patients per group. The project was approved by the Hospital de Clínicas de Porto Alegre Ethics Committee.

Discussion: Considering the aging population, the increased prevalence of multimorbidity and polypharmacy, as well as potential drug interactions and treatment adherence difficulties, an alternative LT4 protocol could be useful for hypothyroidism treatment in the elderly. Prior studies comparing alternative LT4 administration protocols have mainly included young adult populations and have not addressed potential drug interactions.

Trial registration: ClinicalTrials.gov, NCT03614988. Registered 30 July 2018.

Keywords: Aged; Hypothyroidism; Levothyroxine.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart of the MONIALE trial: inclusion criteria, randomization, and follow-up process
Fig. 2
Fig. 2
SPIRIT figure: Allocation, interventions and outcomes

References

    1. World Health Organization . World report on ageing and health. 2015.
    1. United Nations, Department of Economic and Social Affairs, Population Division . World population ageing 2017 - highlights (ST/ESA/SER.A/397) 2017.
    1. Hajat Cother, Stein Emma. The global burden of multiple chronic conditions: A narrative review. Preventive Medicine Reports. 2018;12:284–293. doi: 10.1016/j.pmedr.2018.10.008.
    1. Farmer C, et al. Clinical assessment and management of multimorbidity: summary of NICE guidance. BMJ. 2016;354:1-23. 10.1136/bmj.i4843.
    1. Masnoon N, et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):1–10. doi: 10.1186/s12877-017-0621-2.
    1. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13:57–65. doi: 10.1517/14740338.2013.827660.
    1. Zelko E, Klemencketis Z, Tusekbunc K. Medication adherence in elderly with polypharmacy living at home: a systematic review of existing studies. Mater Sociomed. 2016;28(2):129–132. doi: 10.5455/msm.2016.28.129-132.
    1. Maher Robert L, Hanlon Joseph, Hajjar Emily R. Clinical consequences of polypharmacy in elderly. Expert Opinion on Drug Safety. 2013;13(1):57–65. doi: 10.1517/14740338.2013.827660.
    1. Yarnall AJ, et al. New horizons in multimorbidity in older adults. Age Ageing. 2017;46(6):882–888. doi: 10.1093/ageing/afx150.
    1. Charlesworth CJ, et al. Polypharmacy among adults aged 65 years and older in the United States: 1988–2010. J Gerontol A Biol Sci Med Sci. 2015;70(8):989–995. doi: 10.1093/gerona/glv013.
    1. Canaris GJ, et al. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160(4):526–534. doi: 10.1001/archinte.160.4.526.
    1. Hollowell JG, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III) J Clin Endocrinol Metab. 2002;87(2):489–499. doi: 10.1210/jcem.87.2.8182.
    1. Chaker L, et al. Clinical aspects of thyroid function during ageing. Lancet Diabetes Endocrinol. 2018;6(9):733–742. doi: 10.1016/S2213-8587(18)30028-7.
    1. Vrdoljak D, Borovac JA. Medication in the elderly - considerations and therapy prescription guidelines. Acta Med Acad. 2015;2(44):159–168. doi: 10.5644/ama2006-124.142.
    1. Janiro G, Mangiola F, diRienzo TA. Levothyroxine absorption in health and disease, and new therapeutic perspectives. European review for hypothyroidism. J Thyroid Res. 2011;2011:1–5.
    1. Hays MT. Localization of human thyroxine absorption. Thyroid. 1991;1:241–248. doi: 10.1089/thy.1991.1.241.
    1. Wenzel KW, Kirschsieper HE. Aspects of the absorption of oral L-thyroxine in normal man. Metabolism. 1977;26(1):1–8. doi: 10.1016/0026-0495(77)90121-4.
    1. Hays MT, Nielsen KR. Human thyroxine absorption: age effects and methodological analyses. Thyroid. 1994;4(1):55–64. doi: 10.1089/thy.1994.4.55.
    1. Berg JA, Mayor GH. A study in normal human volunteers to compare the rate and extent of levothyroxine absorption from Synthroid® and Levoxine®. J Clin Pharmacol. 1992;32(12):1135–1140.
    1. Benvenga S, et al. Delayed intestinal absorption of levothyroxine. Thyroid. 1995;5(4):249–253. doi: 10.1089/thy.1995.5.249.
    1. Pabla D, Akhlaghi F, Zia H. A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur J Pharm Biopharm. 2009;72(1):105–110. doi: 10.1016/j.ejpb.2008.10.008.
    1. Centanni M, Gargano L, Canettieri G, Viceconti N, Franchi A, Delle Fave G, Annibale B. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354:1787–1795. doi: 10.1056/NEJMoa043903.
    1. Abi-Abib RC, Vaisman M. Is it necessary to increase the dose of levothyroxine in patients with hypothyroidism who use omeprazole? Arq Bras Endocrinol Metabol. 2014;58(7):731–736. doi: 10.1590/0004-2730000002997.
    1. Hennessey JV. The emergence of levothyroxine as a treatment for hypothyroidism. Endocrine. 2016;55(1):6–18. doi: 10.1007/s12020-016-1199-8.
    1. Campbell NR, Hasinoff BB, Stalts H, et al. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Ann Intern Med. 1992;117:1010–1013. doi: 10.7326/0003-4819-117-12-1010.
    1. Zamfirescu I, Carlson HE. Absorption of levothyroxine when coadministered with various calcium formulations. Thyroid. 2011;21:483–486. doi: 10.1089/thy.2010.0296.
    1. Sperber AD, Liel Y. Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide. Arch Intern Med. 1992;152:183–184. doi: 10.1001/archinte.1992.00400130181024.
    1. Siraj ES, Gupta MK, Reddy SS. Raloxifene causing malabsorption of levothyroxine. Arch Intern Med. 2003;163:1367–1370. doi: 10.1001/archinte.163.11.1367.
    1. John-Kalarickal J, Pearlman G, Carlson HE. New medications which decrease levothryroxineabsorption. Thyroid. 2007;17:763–765. doi: 10.1089/thy.2007.0060.
    1. Northcutt RC, Stiel JN, Hollifield JW, Stant EG. The influence of cholestyramine on thyroxine absorption. JAMA. 1969;208:1857–1861. doi: 10.1001/jama.1969.03160100047012.
    1. Goldberg AS, Tirona RG, Asher LJ, et al. Ciprofloxacin and rifampin have opposite effects on levothtroxine absorption. Thyroid. 2013;23:1374–1378. doi: 10.1089/thy.2013.0014.
    1. Jonklaas J, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670–1751. doi: 10.1089/thy.2014.0028.
    1. Vaisman F, et al. How good is the levothyroxine replacement in primary hypothyroidism patients in Brazil? Data of a multicentre study. J Endocrinol Invest. 2013;36(7):485–488. doi: 10.3275/8810.
    1. Bagattoli RM, Vaisman M, Lima JS, Ward LS. Estudo de Adesão ao Tratamento do Hipotiroidismo. Arq Braz Endocrinol Metab. 2000;44(2):483–487. doi: 10.1590/S0004-27302000000600006.
    1. Benvenga S, Bartolone L, Pappalardo MA, et al. Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid. 2008;18:293–301. doi: 10.1089/thy.2007.0222.
    1. Conrad SC, Chiu H, Silverman BL. Soy formula complicates management of congenital hypothyroidism. Arch Dis Child. 2004;89:37–40. doi: 10.1136/adc.2002.009365.
    1. Lilja JJ, Laitinen K, Neuvonen PJ. Effects of grapefruit juice on the absorption of levothyroxine. Br J Clin Pharmacol. 2005;60:337–341. doi: 10.1111/j.1365-2125.2005.02433.x.
    1. Chon DA, et al. Concurrent milk ingestion decreases absorption of levothyroxine. Thyroid. 2018;28(4):454–457. doi: 10.1089/thy.2017.0428.
    1. Bolk Nienke, Visser Theo J., Kalsbeek Andries, van Domburg Ron T., Berghout Arie. Effects of evening vs morning thyroxine ingestion on serum thyroid hormone profiles in hypothyroid patients. Clinical Endocrinology. 2006;0(0):061019025934001-???. doi: 10.1111/j.1365-2265.2006.02681.x.
    1. Bolk N. Effects of evening vs morning levothyroxine intake. Arch Intern Med. 2010;170(22):1996–2003. doi: 10.1001/archinternmed.2010.436.
    1. Rajput R, Chatterjee S, Rajput M. Can levothyroxine be taken as evening dose? Comparative evaluation of morning vs. evening dose of levothyroxine in treatment of hypothyroidism. J Thyroid Res. 2011;2011:1–5. doi: 10.4061/2011/505239.
    1. Bach-Huynh T-g, et al. Timing of levothyroxine administration affects serum thyrotropin concentration. J Clin Endocrinol Metab. 2009;94(10):3905–3912. doi: 10.1210/jc.2009-0860.
    1. Perez CLS, et al. Serum thyrotropin levels following levothyroxine administration at breakfast. Thyroid. 2013;23(7):779–784. doi: 10.1089/thy.2012.0435.
    1. Skelin M, et al. Effect of timing of levothyroxine administration on the treatment of hypothyroidism: a three-period crossover randomized study. Endocrine. 2018;62(2):432–439. doi: 10.1007/s12020-018-1686-1.
    1. Chan An-Wen, Tetzlaff Jennifer M., Altman Douglas G., Laupacis Andreas, Gøtzsche Peter C., Krleža-Jerić Karmela, Hróbjartsson Asbjørn, Mann Howard, Dickersin Kay, Berlin Jesse A., Doré Caroline J., Parulekar Wendy R., Summerskill William S.M., Groves Trish, Schulz Kenneth F., Sox Harold C., Rockhold Frank W., Rennie Drummond, Moher David. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Annals of Internal Medicine. 2013;158(3):200. doi: 10.7326/0003-4819-158-3-201302050-00583.
    1. Senn S. Cross-over trials in clinical research. 2. London: Wiley; 2002.
    1. Colucci P, et al. A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. Eur Endocrinol. 2010;9(1):40–47. doi: 10.17925/ee.2013.09.01.40.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit